drug

brincidofovir

1 story · latest Aug 5, 2026

Status: FDA approved Jun 2021 · NDA214460, NDA214461
Brand: Tembexa

Timeline

Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlook

Aug 5RestructuringEmergent BioSolutions

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.